Name: CYBIN INC (CYBN) Stock
Brand: CYBIN INC
Rating: 4 (3 reviews)

CYBN Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Cybin Inc. - Mentions: CBOE

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

a month ago - By: Cybin Inc. - Mentions: CBOE

Cybin to Participate in the Jefferies Global Healthcare Conference in London

a month ago - By: Cybin Inc. - Mentions: CBOE

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

a month ago - By: Benzinga - Mentions: ECC VINP INV VTGN ...

Earnings Scheduled For November 13, 2025

a month ago - By: Benzinga

What's Next: Cybin's Earnings Preview

a month ago - By: Cybin Inc. - Mentions: CBOE

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

a month ago - By: Cybin Inc. - Mentions: CBOE

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

a month ago - By: Cybin Inc. - Mentions: CBOE

Cybin Announces Closing of $175 Million Registered Direct Offering

2 months ago - By: Cybin Inc. - Mentions: CBOE

Cybin Announces $175 Million Registered Direct Offering

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: Cybin Inc.

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: The Schall Law Firm

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

3 months ago - By: Cybin Inc.

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

3 months ago - By: Cybin Inc.

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

3 months ago - By: Cybin Inc.

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Yahoo Finance - Mentions: DB PEP UTHR STZ ...

Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint

3 months ago - By: Cybin Inc.

Cybin to Participate in the Cantor Global Healthcare Conference 2025

3 months ago - By: Cybin Inc.

Cybin Announces Senior Leadership Changes

4 months ago - By: Cybin Inc.

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

4 months ago - By: Cybin Inc.

Cybin Announces Results of Annual Meeting of Shareholders

4 months ago - By: Cybin Inc.

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

4 months ago - By: Cybin Inc.

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

4 months ago - By: Cybin Inc.

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

5 months ago - By: Cybin Inc.

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

6 months ago - By: Cybin Inc.

CYBIN INC (CYBN) Stock News

CYBN Latest News, Press Relases and Analysis

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Earnings Scheduled For November 13, 2025

What's Next: Cybin's Earnings Preview

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures